Fortrea Holdings Inc. (FTRE) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ Operating Improvement ā¢ Liquidity Pressure ā¢ High Leverage FTRE showed better near-term operating performance with positive EBITDA and stable gross margin in Q1 2026, but persistent net losses, weak liquidity, and heavy leverage keep the financial profile high risk.
Price Behavior
Key Price Behavior Insights: ā¢ Support Hold ā¢ Breakout Confirmed ā¢ Overbought Pullback Support Level: $15.0-$15.4 Resistance Level: $17.25 FTRE's last month recovery looks constructive after defending $13.1-$13.4 and breaking above $15.0-$15.4, but the stock is stretched short term with $17.25 acting as resistance.
Sentiment & News
Key News Insights: ā¢ Leadership Presence ā¢ Investor Outreach ā¢ No New Update Fortrea will have its CEO, CFO, and IR leader at Jefferies' Global Healthcare Conference, signaling investor outreach and visibility rather than a new operating update.
AI Summary
FTRE has shifted from a broken story to a credible turnaround, with sustained >1.1x book-to-bill, a $7.8B backlog, and reaffirmed 2026 guidance showing real operating traction, but the investment case still hinges on converting EBITDA into free cash flow fast enough to reduce leverage and avoid balance-sheet stress.
Description
Fortrea Holdings Inc. is a contract research organization that provides development services for biopharmaceuticals and medical devices globally. Its operations are organized into Clinical Services, covering clinical pharmacology and the spectrum of clinical development, and Enabling Services, which supplies patient access, trial technology, randomization and drug supply support. The company delivers these capabilities through full-service, functional service provider and hybrid models and also offers phase IāIV trial management and post-approval support; it was incorporated in 2023 and is based in Durham, North Carolina.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 4 | Dec 11 | FTRE | Fortrea Holdings Inc. | Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management. | Closed | +7.2% |